Corrigendum: Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes

Corrigendum: Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes

Bibliographic Details
Main Author:	Carolyn F. Deacon
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2019-05-01
Series:	Frontiers in Endocrinology
Subjects:	dipeptidyl peptidase-4 glucagon-like peptide-1 incretin peptide degradation therapy type 2 diabetes
Online Access:	https://www.frontiersin.org/article/10.3389/fendo.2019.00275/full

Similar Items

Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
by: Carolyn F. Deacon
Published: (2019-02-01)

Dipeptidyl Peptidase (DPP)-IV Inhibitors with Antioxidant Potential Isolated from Natural Sources: A Novel Approach for the Management of Diabetes
by: Anand-Krishna Singh, et al.
Published: (2021-06-01)

Pathogenetic substantiation and effectiveness of vildagliptin use inpatients with diabetes mellitus type 2
Published: (2009-09-01)

Comparative effects of incretin-based therapy on doxorubicin-induced nephrotoxicity in rats: the role of SIRT1/Nrf2/NF-κB/TNF-α signaling pathways
by: Sandy R. Botros, et al.
Published: (2024-02-01)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
by: Ahren B
Published: (2010-03-01)

Las incretinas como nueva opción terapéutica en la diabetes mellitus tipo 2
by: Félix Andrés Reyes Sanamé, et al.

Incretins as a Potential Treatment Option for Gestational Diabetes Mellitus
by: Aleksandra Pilszyk, et al.
Published: (2022-09-01)

Role of Incretin Axis in Inflammatory Bowel Disease
by: Lihua Duan, et al.
Published: (2017-12-01)

Functional foods with dipeptidyl peptidase‐4 inhibitory potential and management of type 2 diabetes: A review
by: Mutiu Kazeem, et al.
Published: (2021-06-01)

Clinical and Physiological Characterization of Elevated Plasma Glucagon-Like Peptide-1 Levels (Hyperglipemia) in a Dipeptidyl Peptidase IV Mutation Carrier
by: Dandan Zhao, et al.
Published: (2018-03-01)

Lechenie sakharnogo diabeta 2 tipa ingibitorami dipeptidilpeptidazy-4
Published: (2010-09-01)

Incretin-based therapy: renal effects
by: Anton Ivanovich Korbut, et al.
Published: (2016-01-01)

Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions
by: Awadhesh Kumar Singh
Published: (2014-01-01)

Influence of Diet and Gender on Plasma DPP4 Activity and GLP-1 in Patients with Metabolic Syndrome: An Experimental Pilot Study
by: Francisco Tomás Pérez-Durillo, et al.
Published: (2018-06-01)

The high need for trials assessing functional outcome after stroke rather than stroke prevention with GLP-1 agonists and DPP-4 inhibitors
by: Vladimer Darsalia, et al.
Published: (2018-02-01)

Endogenous GLP-1 levels play an important role in determining the efficacy of DPP-IV Inhibitors in both prediabetes and type 2 diabetes
by: Shiau Chin Chong, et al.
Published: (2022-10-01)

Acute and Chronic Exposure to Linagliptin, a Selective Inhibitor of Dipeptidyl Peptidase-4 (DPP-4), Has an Effect on Dopamine, Serotonin and Noradrenaline Level in the Striatum and Hippocampus of Rats
by: Małgorzata Łupina, et al.
Published: (2024-03-01)

DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
by: Michael Razavi, et al.
Published: (2022-08-01)

The regulatory role of DPP4 in atherosclerotic disease
by: Lihua Duan, et al.
Published: (2017-06-01)

The associations of incretin hormone concentration with gestational diabetes mellitus
by: Tatiana V. Saprina, et al.
Published: (2016-05-01)

Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential
by: Nasser Mikhail
Published: (2008-12-01)

Exposure–Response Analysis of Cardiovascular Outcome Trials With Incretin-Based Therapies
by: Qi Pan, et al.
Published: (2022-05-01)

Receptor-Mediated Bioassay Reflects Dynamic Change of Glucose-Dependent Insulinotropic Polypeptide by Dipeptidyl Peptidase 4 Inhibitor Treatment in Subjects With Type 2 Diabetes
by: Tsuyoshi Yanagimachi, et al.
Published: (2020-04-01)

A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus
by: Ira Gantz, et al.
Published: (2017-09-01)

Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?
by: Giuseppe Lisco, et al.
Published: (2023-10-01)

Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes
by: Nina A. Petunina, et al.
Published: (2018-09-01)

Association Between Diabetes Medications and the Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis
by: Xiaocui Qin, et al.
Published: (2021-07-01)

Vildagliptin, a dipeptidyl peptidase-4 inhibitor, attenuated endothelial dysfunction through miRNAs in diabetic rats
by: Qian Zhang, et al.
Published: (2019-07-01)

Quassia amara bioactive compounds as a Novel DPP-IV inhibitor: an in-silico study
by: Ezekiel A. Olugbogi, et al.
Published: (2022-07-01)

Anti-atherosclerotic effect of incretin mimetics: a meta-analysis of randomized controlled trials
by: Mahmoud Barbarawi, et al.
Published: (2018-11-01)

Secretion of incretin hormones in people having risk factors for type 2 diabetes mellitus
by: E A Shestakova, et al.
Published: (2014-10-01)

Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
by: Gagik R. Galstyan, et al.
Published: (2017-10-01)

Liraglutide; A New Hope for Obese Diabetics
by: Ajeet Kumar, et al.
Published: (2020-12-01)

A review on phytochemical and pharmacological facets of tropical ethnomedicinal plants as reformed DPP-IV inhibitors to regulate incretin activity
by: Srishti Chhabria, et al.
Published: (2022-11-01)

Pharmalogical effects and results of clinical trials of the first incretinomimetic exenatide
by: Alexander Sergeevich Ametov, et al.
Published: (2011-09-01)

Gastrointestinal Incretins—Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) beyond Pleiotropic Physiological Effects Are Involved in Pathophysiology of Atherosclerosis and Coronary Artery Disease—State of the Art
by: Szymon Jonik, et al.
Published: (2022-02-01)

Strong Association between Plasma Dipeptidyl Peptidase-4 Activity and Impaired Cognitive Function in Elderly Population with Normal Glucose Tolerance
by: Bo Chen, et al.
Published: (2017-07-01)

Glucagon-like peptide-1 analogues: An overview
by: Vishal Gupta
Published: (2013-01-01)

Effects of Incretin-Based Therapies on Diabetic Microvascular Complications
by: Yu Mi Kang, et al.
Published: (2017-09-01)

Patterns and trends of utilization of incretin-based medicines between 2008 and 2014 in three Italian geographic areas
by: Giuseppe Roberto, et al.
Published: (2019-02-01)